We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
-7.79%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
+$7.74M
Cap. Flow
+$19.6M
Cap. Flow %
1.57%
Top 10 Hldgs %
54.36%
Holding
75
New
18
Increased
14
Reduced
16
Closed
18

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$51.7M
2
RVMD icon
Revolution Medicines
RVMD
+$44.9M
3
MRUS
Merus
MRUS
+$41.2M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$31.8M
5
IRON icon
Disc Medicine
IRON
+$31.4M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$58.5M
2
DYN icon
Dyne Therapeutics
DYN
+$42.6M
3
IMVT icon
Immunovant
IMVT
+$34.1M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$32.1M
5
GERN icon
Geron
GERN
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 69.8%
2 Miscellaneous 30.2%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
51
DELISTED
Adverum Biotechnologies
ADVM
$2.86M 0.23%
416,666
-1,083,333
-72% -$10.1M
APLT
52
DELISTED
Applied Therapeutics
APLT
$2.66M 0.21%
600,000
-750,000
-56% -$3.55M
RNAC icon
53
Cartesian Therapeutics
RNAC
$238M
$2.43M 0.2%
+90,000
New +$2.15M
UNCY icon
54
Unicycive Therapeutics
UNCY
$133M
$1.74M 0.14%
346,993
– –
IOBT
55
DELISTED
IO Biotech
IOBT
$578K 0.05%
493,827
– –
BOLD
56
Boundless Bio
BOLD
$63.7M
$433K 0.03%
117,806
-82,194
-41% -$786K
NUVB.WS
57
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$10.7K ﹤0.01%
66,666
– –
ALNY icon
58
CALL
Alnylam Pharmaceuticals
ALNY
$32.9B
– –
-500,000
Closed -$74.7M
ATXS
59
CALL
DELISTED
Astria Therapeutics
ATXS
– –
-1,000,000
Closed -$14.1M
CGEM icon
60
Cullinan Oncology
CGEM
$1.37B
– –
-700,000
Closed -$11.9M
CGON icon
61
CG Oncology
CGON
$6.7B
– –
-300,000
Closed -$13.2M
CLDX icon
62
Celldex Therapeutics
CLDX
$3.06B
– –
-650,000
Closed -$27.3M
CYTK icon
63
Cytokinetics
CYTK
$9.72B
– –
-100,000
Closed -$7.01M
GERN icon
64
Geron
GERN
$848M
– –
-9,000,000
Closed -$29.7M
IMCR icon
65
Immunocore
IMCR
$1.66B
– –
-900,000
Closed -$58.5M
IMTX icon
66
Immatics
IMTX
$1.34B
– –
-1,000,000
Closed -$10.5M
IMUX icon
67
Immunic
IMUX
$141M
– –
-42,118
Closed -$556K
KURA icon
68
Kura Oncology
KURA
$1.04B
– –
-300,000
Closed -$6.4M
CYPH
69
Cypherpunk Technologies Inc
CYPH
$331M
– –
-39,500
Closed -$105K
LRMR icon
70
CALL
Larimar Therapeutics
LRMR
$395M
– –
-700,000
Closed -$5.31M
PRAX icon
71
Praxis Precision Medicines
PRAX
$8.67B
– –
-150,000
Closed -$9.15M
SNDX icon
72
Syndax Pharmaceuticals
SNDX
$1.58B
– –
-350,000
Closed -$8.33M
TRML
73
DELISTED
Tourmaline Bio
TRML
– –
-99,208
Closed -$2.27M
VRDN icon
74
Viridian Therapeutics
VRDN
$2.48B
– –
-700,000
Closed -$12.3M
KYTX icon
75
Kyverna Therapeutics
KYTX
$435M
– –
-500,000
Closed -$12.4M
1 2
3

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q2 2024 Portfolio in Review

As of Q2 2024, Logos Global Management held 75 positions worth $1.24B, up 0.63% from $1.24B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Logos Global Management's Q2 2024 filing shows 18 new, 14 increased, 16 reduced and 18 closed positions. Its largest new stake was argenx: 135,000 shares worth $58.1M. The largest sale was Immunocore, an estimated $58.5M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 77% a quarter earlier, followed by Miscellaneous and Financials.

  • Logos Global Management's largest Q2 2024 buy was argenx: 135,000 shares worth $58.1M.
  • Logos Global Management added most to Janux Therapeutics in Q2 2024, an estimated $28.2M increase.
  • Logos Global Management's biggest Q2 2024 reduction was Dyne Therapeutics, cutting an estimated $42.6M.
  • Logos Global Management fully exited Immunocore in Q2 2024, selling an estimated $58.5M.
  • Logos Global Management's ten largest holdings make up 54% of its $1.24B portfolio in Q2 2024.
  • Logos Global Management opened 18 new positions and closed 18 in Q2 2024.
  • Logos Global Management's portfolio value rose 0.63% quarter-over-quarter to $1.24B.

Based on Logos Global Management's 13F filing for Q2 2024, filed 14 Aug 2024.